Last reviewed · How we verify
enoxaparin ,alteplase, unfractionated heparin
At a glance
| Generic name | enoxaparin ,alteplase, unfractionated heparin |
|---|---|
| Sponsor | Ataturk University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism (PHASE3)
- Clot Dissolving Treatment for Blood Clots in the Lungs (PHASE3)
- The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI (PHASE4)
- Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE (PHASE3)
- Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism (PHASE4)
- STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction (PHASE3)
- XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (PHASE4)
- Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: